GlobeNewswire

Mitratech’s TAP Workflow Automation Gains Momentum with New Customers and Launches New Features at ACC EUROPE to Advance the Practice of Legal Operations

Share

New TAPSign Electronic Signature and Work Flow Sharing Enhance Document Management and Collaboration

SLOUGH, England, May 13, 2019 (GLOBE NEWSWIRE) -- Mitratech announced at ACC EUROPE 2019 today new capabilities and benefits for its rapidly growing community of customers using TAP Workflow Automation to innovate and automate legal processes. TAP was added to Mitratech’s proven portfolio of end-to-end solutions in April 2018. Over the past year, 26 new legal departments have selected TAP to extend services and operations across the enterprise.

Additionally, TAP now includes TAPSign electronic signature strengthening the management of documents and forms such as contracts, NDA’s retention letters, partner and supplier agreements, and virtually any other internal approval. TAPSign empowers clients to digitally accelerate business processes and comply with sustainability efforts to replace paper with digital forms and documents.

The latest TAP release also includes simple, one-click import and export capability for bringing in new workflow designs or sharing them out with others. With this capability in place, Mitratech also announced a new TAP Co-Innovation Center. Customers can go to the Co-Innovation Center to view the process automation ideas and use cases of their peers, and at their discretion, can now easily share workflows. This capability is a cornerstone to the overall theme of co-innovation between customers, employees and partners that permeates across the TAP ecosystem, and is transforming the legal operations community.

“Through Mitratech’s TAP Co-Innovation Center, we realize the opportunity to develop and share ideas on how we can use TAP to improve – if not eliminate – effort heavy, high volume/low risk business processes in our organization and between our Legal systems,” said Greg Bennett, senior manager, legal operations, Gilead Sciences. “More importantly, the Innovation Center provides a front-row seat to see how this technology is rapidly shaping a new landscape in the legal business.”

“Mitratech could not be more excited about the innovation we are seeing in the delivery of legal services across the legal operations and TAP community,” said Mitratech CEO Jason Parkman. “Our customers are creating true Legal Service Centers that improve outcomes by promoting innovation and excellence across not just the legal department, but the entire enterprise.”

At the ACC EUROPE 2019 conference, Mitratech’s Tim Wilson will present “The Rise of (Wearing the Glasses of) the Chief Legal Operations Officer” with Elisabeth De Dobbeleer, Vice President & Deputy General Counsel, EMEAR, Cisco Systems Belgium, Chris Fowler, General Counsel BT Technology and Transformation, British Telecom and Mo Zain Ajaz, Chief Operations Officer for Legal and General Counsel, National Grid. Mitratech invites anyone attending ACC EUROPE 2019 to join the session or stop by the Mitratech stand #18 to learn more about its solutions for legal operations.

ABOUT MITRATECH:
Mitratech is a proven global technology partner for corporate legal professionals who seek out and maximize opportunities to raise productivity, control expenses, and mitigate risk by deepening organizational alignment, increasing visibility, and spurring collaboration across the enterprise. Serving 1,200 organizations of all sizes across the globe, we represent almost 40 percent of the Fortune 500 and over 500,000 users in over 160 countries.

With Mitratech’s proven portfolio of end-to-end solutions, operational best practices spread throughout the enterprise, standardizing processes and accelerating time-to-value. By unlocking every opportunity to drive progress and improve outcomes, Mitratech is helping legal teams rise to the challenge of serving the evolving needs of the modern, dynamic enterprise. For more information, visit https://www.mitratech.com/.

MEDIA CONTACT:

Sue Huss
Mitratech
sue.huss@mitratech.com
619-379-4396

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Hofseth Biocare ASA: ENTERS INTO A CONSULTANCY AGREEMENT WITH JAMES BERGER – CONTEMPLATED US LISTING18.10.2019 08:05:00 CESTPress release

Hofseth BioCare ASA ("HBC") has today entered into a consultancy agreement with James Berger (through his company Nevera AG). Mr. Berger is a dual British and Italian citizen currently residing in Switzerland who has previously worked as an investment banker with Goldman Sachs International (London), JP Morgan (London), MAN Investments PLC and Millennium Capital Management LLC. He has a broad network with the largest investment banks and institutional investors in Europe and globally. Mr. Berger has already successfully assisted HBC with its oversubscribed private placement of NOK 118 million that was directed towards international private investors and institutional funds. He has recently also facilitated the sale of additional shares in HBC from certain existing shareholders to new international investors. Under the consultancy agreement, Mr. Berger will assist HBC with certain intermediary services, in establishing a wider base of international investors. Mr. Berger and HBC believe

Yara announces share buy-backs18.10.2019 08:02:00 CESTPress release

Oslo, 18 October 2019: Yara International ASA plans to buy back 0.5% of its outstanding shares by the end of 2019. Including the proportional redemption of shares owned by the Norwegian state, the total buyback and redemption will amount to approximately 0.8% of shares outstanding, equivalent to approximately NOK 800 million at today’s share price. Yara's targeted capital structure is a mid- to long-term Net debt/EBITDA range of 1.5-2.0 and a net debt/equity ratio below 0.60. Subject to these requirements, Yara's ordinary dividend shall be 50% of net income. Shareholder returns are distributed primarily as cash, with share buy-backs as a supplemental lever. Yara’s net debt/EBITDA as of 30 September 2019 would be close to 2.0 including the full effect of the announced buyback. The buy-backs are part of a program authorized by the Annual General meeting held 7 May 2019, which authorized Yara to buy back up to 5% (13,620,131 shares) of its share capital before its 2020 Annual General Meet

Yara reports higher results, delivering operational and commercial improvement18.10.2019 08:00:00 CESTPress release

Oslo, 18 October 2019: Third-quarter net income after non-controlling interests was USD 74 million (USD 0.27 per share), compared with USD 98 million (USD 0.36 per share) a year earlier. Excluding currency effects and special items, the result was USD 0.94 per share compared with USD 0.50 per share in third quarter 2018 . Third-quarter EBITDA excluding special items was USD 630 million, up from USD 402 million a year earlier, mainly reflecting higher nitrogen upgrading margins and strong premium product deliveries. “Yara delivers significantly improved results in third quarter, with EBITDA excluding special items and IFRS 16 up 49%. The results reflect lower energy cost, higher production and strong premium product deliveries,” said Svein Tore Holsether, President and Chief Executive Officer of Yara. "I am pleased to see our results improve within all business segments, with the strongest increase in New Business. Our return on capital continues its positive trend, and our main priorit

Yara med høyere resultat, operasjonell og kommersiell forbedring18.10.2019 08:00:00 CESTPressemelding

Oslo, 18. oktober 2019: Nettoresultat etter minoritetsinteresser for tredje kvartal var på USD 74 millioner (USD 0,27 per aksje), mot USD 98 millioner (USD 0,36 per aksje) for samme periode i fjor. Korrigert for valutaeffekter og spesielle poster var resultatet på USD 0,94 per aksje, mot USD 0,50 per aksje i tredje kvartal 2018. EBITDA eksklusive spesielle poster for tredje kvartal var på USD 630 millioner, opp fra USD 402 millioner ett år tidligere, og reflekterer høyere nitrogen oppgraderingsmarginer og sterke premium-leveranser. «Yara leverer betydelig bedre resultater i andre kvartal, med EBITDA eksklusive spesielle poster og IFRS 16 opp 49 %. Resultatet reflekterer lavere energikostnader, høyere produksjon og sterke premium-leveranser» sier Svein Tore Holsether, konsernsjef i Yara. «Jeg er fornøyd med at vi leverer resultatforbedring innen alle forretningsområder, med sterkest økning i New Business. Yaras avkastning fortsetter å øke, og hovedprioriteten fremover vil fortsatt være

SBM Offshore successful bidder for partner’s minority ownership in SBM Offshore operated FPSO companies18.10.2019 07:30:00 CESTPress release

October 18, 2019 Further to the announcement dated September 30, 2019 confirming its participation in the public sale auction of the equity ownership of Serviços de Petróleo Constellation S.A. (“Constellation”) in the lease and operating companies related to five Brazilian FPSOs (“the entities”), SBM Offshore confirms it has been formally designated as the successful bidder. Completion of the transaction remains subject to various conditions precedent, including consent from client Petrobras and approval by the local antitrust authority CADE (“Conselho Administrativo de Defesa Econômica”). The total consideration for the equity ownership, excluding associated non-recourse project debt, is c. US$150 million. The transaction includes the minority stake held by affiliated companies of Constellation in the entities related to the following five FPSOs (with Constellation’s ownership percentage in brackets): Cidade de Paraty (20%), Cidade de Ilhabela (12.75%), Cidade de Marica (5%), Cidade d

Roche announces FDA approval of Xofluza (baloxavir marboxil) for people at high risk of developing influenza-related complications18.10.2019 07:00:00 CESTPress release

Single-dose Xofluza is the first and only antiviral medicine indicated specifically for patients at high risk of developing serious complications from influenza (flu) The Centers for Disease Control and Prevention (CDC) defines people at high risk of serious flu complications as those who have conditions such as asthma, chronic lung disease, diabetes, heart disease or morbid obesity, or adults 65 years of age or older1 Basel, 18 October 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Xofluza™ (baloxavir marboxil) for the treatment of acute, uncomplicated influenza, or flu, in people 12 years of age and older who have been symptomatic for no more than 48 hours and who are at high risk of developing flu-related complications. Xofluza is a first-in-class, one-dose oral medicine with a novel proposed mechanism of action that inhibits polymerase acidic endonuclease, an enzyme